TR201812823T4 - Lipopeptit bileşimleri ve ilgili yöntemler. - Google Patents

Lipopeptit bileşimleri ve ilgili yöntemler. Download PDF

Info

Publication number
TR201812823T4
TR201812823T4 TR2018/12823T TR201812823T TR201812823T4 TR 201812823 T4 TR201812823 T4 TR 201812823T4 TR 2018/12823 T TR2018/12823 T TR 2018/12823T TR 201812823 T TR201812823 T TR 201812823T TR 201812823 T4 TR201812823 T4 TR 201812823T4
Authority
TR
Turkey
Prior art keywords
related methods
lipopeptide compositions
compositions
daptomycin
lipopeptide
Prior art date
Application number
TR2018/12823T
Other languages
English (en)
Inventor
Sun Sophie
Naik Gaauri
O'connor Sandra
Original Assignee
Cubist Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201812823(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals Llc filed Critical Cubist Pharmaceuticals Llc
Publication of TR201812823T4 publication Critical patent/TR201812823T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Mevcut buluş, katı halde olduğunda daha gelişmiş kimyasal stabiliteye ve daha hızlı sulandırma sürelerine sahip olan yeni toz daptomisin formülasyonları sağlar. Bileşimlerin bazı örnekleri daptomisin ve sükroz içerir.
TR2018/12823T 2009-11-23 2010-11-23 Lipopeptit bileşimleri ve ilgili yöntemler. TR201812823T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
TR201812823T4 true TR201812823T4 (tr) 2019-02-21

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/12823T TR201812823T4 (tr) 2009-11-23 2010-11-23 Lipopeptit bileşimleri ve ilgili yöntemler.

Country Status (33)

Country Link
US (3) US8835382B2 (tr)
EP (2) EP2504353B2 (tr)
JP (3) JP6041673B2 (tr)
CN (3) CN108785654A (tr)
AR (2) AR079127A1 (tr)
AU (1) AU2010321531C1 (tr)
BR (1) BR112012012406B1 (tr)
CA (1) CA2781666C (tr)
CL (2) CL2012001336A1 (tr)
CO (1) CO6541585A2 (tr)
CR (1) CR20120271A (tr)
CY (1) CY1120854T1 (tr)
DK (1) DK2504353T4 (tr)
DO (1) DOP2012000140A (tr)
EC (1) ECSP12011939A (tr)
ES (1) ES2686331T5 (tr)
FI (1) FI2504353T4 (tr)
HR (1) HRP20181380T4 (tr)
HU (1) HUE039967T2 (tr)
IL (1) IL219891B (tr)
LT (1) LT2504353T (tr)
MX (1) MX2012005993A (tr)
NZ (1) NZ600118A (tr)
PE (2) PE20151717A1 (tr)
PL (1) PL2504353T5 (tr)
PT (1) PT2504353T (tr)
RS (1) RS57566B2 (tr)
RU (1) RU2607526C2 (tr)
SG (1) SG10201407724YA (tr)
SI (1) SI2504353T2 (tr)
TR (1) TR201812823T4 (tr)
TW (2) TWI606838B (tr)
WO (1) WO2011063419A2 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
CA2823628A1 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
CA2837174A1 (en) * 2011-05-26 2012-11-29 Cubist Pharmaceuticals, Inc. Cb-183,315 compositions and related methods
CN104168908A (zh) * 2012-01-12 2014-11-26 细胞基因公司 罗米地新制剂及其用途
CA2881121A1 (en) * 2012-08-23 2014-03-27 Agila Specialties Private Limited Improved daptomycin injectable formulation
NZ706286A (en) 2012-09-11 2018-05-25 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
MX2020001885A (es) * 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
CN114828873A (zh) * 2019-12-26 2022-07-29 尼普洛株式会社 含有达托霉素的稳定的冷冻干燥制剂
CN115038431B (zh) 2020-02-28 2024-08-09 埃克斯利亚制药有限公司 达托霉素制剂
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
KR102218688B1 (ko) * 2020-06-25 2021-02-22 주식회사 클린텍 무선제어기능을 구비한 고압세척기
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
SU1452484A3 (ru) 1984-10-09 1989-01-15 Эли Лилли Энд Компани (Фирма) Способ получени производных антибиотиков А-21978С, штамм стрептомицета SтRертомYсеS RoSeoSpoRUS, используемый дл получени антибиотических веществ А-21978С
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
ES2110405T3 (es) 1990-01-26 1998-02-16 Hoechst Ag Un nuevo antibiotico, desoximulundocandina, un procedimiento para su produccion y su uso como medicamento.
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (tr) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) * 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
WO1993021207A1 (en) 1992-04-20 1993-10-28 Abbott Laboratories Process for making vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
CN1530136A (zh) 1998-09-25 2004-09-22 ������ҩ�����޹�˾ 抗生素的给药方法
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
CA2394350A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
ATE535539T1 (de) * 2000-12-18 2011-12-15 Cubist Pharm Inc Verfahren zur herstellung gereinigter lipopeptide
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重t細胞エピトープポリペプチドの酢酸塩組成物
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
ATE325140T1 (de) 2002-01-17 2006-06-15 Arkema Supramolekularpolymere
CA2491474A1 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−11含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
KR20070085674A (ko) * 2005-02-14 2007-08-27 비너스 레머디스 리미티드 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ, インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
EP1919449A2 (en) 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0715113A2 (pt) * 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
JP5143841B2 (ja) 2006-10-10 2013-02-13 ロス アラモス ナショナル セキュリティー,エルエルシー 高度な薬物開発及び製造
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
AU2008269140A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
CA2703597A1 (en) * 2007-10-25 2009-04-30 Novartis Ag Powder conditioning of unit dose drug packages
WO2009144739A1 (en) * 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
EP2504020A4 (en) 2009-11-23 2013-05-29 Eagle Pharmaceuticals Inc DAPTOMYCIN FORMULATIONS
KR20140022773A (ko) 2010-11-01 2014-02-25 립-엑스 파마슈티칼즈, 인크. 약학 조성물
CA2822447C (en) 2010-12-23 2018-05-01 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法

Also Published As

Publication number Publication date
CY1120854T1 (el) 2019-12-11
DK2504353T3 (en) 2018-09-10
CR20120271A (es) 2012-08-01
IL219891A0 (en) 2012-07-31
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
US9138456B2 (en) 2015-09-22
PL2504353T3 (pl) 2018-11-30
JP2013511557A (ja) 2013-04-04
AU2010321531A2 (en) 2014-10-30
RS57566B2 (sr) 2023-12-29
US9662397B2 (en) 2017-05-30
PE20151717A1 (es) 2015-11-19
HRP20181380T4 (hr) 2023-11-10
AU2010321531B2 (en) 2016-11-03
DOP2012000140A (es) 2012-10-30
US8835382B2 (en) 2014-09-16
PL2504353T5 (pl) 2023-11-20
SG10201407724YA (en) 2014-12-30
PE20121517A1 (es) 2012-11-26
US20140364380A1 (en) 2014-12-11
CL2012001336A1 (es) 2012-10-05
US20160030577A1 (en) 2016-02-04
CN108785654A (zh) 2018-11-13
DK2504353T4 (da) 2023-11-20
FI2504353T4 (fi) 2023-11-30
JP2016147874A (ja) 2016-08-18
AR079127A1 (es) 2011-12-28
ES2686331T3 (es) 2018-10-17
ECSP12011939A (es) 2012-07-31
AR123846A2 (es) 2023-01-18
EP3417849A1 (en) 2018-12-26
EP2504353A2 (en) 2012-10-03
EP2504353B2 (en) 2023-09-13
ES2686331T5 (es) 2024-03-27
EP2504353A4 (en) 2014-04-02
PT2504353T (pt) 2018-10-18
SI2504353T2 (sl) 2023-11-30
WO2011063419A2 (en) 2011-05-26
IL219891B (en) 2018-01-31
WO2011063419A3 (en) 2011-10-13
TWI548414B (zh) 2016-09-11
AU2010321531C1 (en) 2020-10-01
LT2504353T (lt) 2018-09-25
RU2012126076A (ru) 2013-12-27
BR112012012406A2 (pt) 2019-12-03
CN102712677A (zh) 2012-10-03
AU2010321531A1 (en) 2012-06-14
CO6541585A2 (es) 2012-10-16
CA2781666C (en) 2017-02-21
JP6239167B2 (ja) 2017-11-29
HRP20181380T1 (hr) 2018-10-19
CN102712677B (zh) 2015-06-03
NZ600118A (en) 2014-08-29
JP6041673B2 (ja) 2016-12-14
EP2504353B1 (en) 2018-07-11
HUE039967T2 (hu) 2019-02-28
TW201703791A (zh) 2017-02-01
RU2607526C2 (ru) 2017-01-10
JP2017075186A (ja) 2017-04-20
US20120270772A1 (en) 2012-10-25
JP6088681B2 (ja) 2017-03-01
MX2012005993A (es) 2012-11-23
CN104056250A (zh) 2014-09-24
RS57566B1 (sr) 2018-10-31
CA2781666A1 (en) 2011-05-26
BR112012012406B1 (pt) 2021-11-16
CL2015002412A1 (es) 2016-02-05
SI2504353T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
TR201812823T4 (tr) Lipopeptit bileşimleri ve ilgili yöntemler.
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2011130222A3 (en) Compositions and methods comprising variant proteases
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
EA201201000A1 (ru) Способы лечения колоректального рака
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012012955A (es) Particulas porosas de oxido inorganico y metodos para preparar y utilizar los mismos.
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
EA201270377A1 (ru) Стабильные композиции sns-595 и способы их получения
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
MY165088A (en) Pharmaceutical compositions comprising alisporivir
TR201009168A2 (tr) Suda dağılan sefpodoksim proksetil formülasyonları.
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
WO2012174164A3 (en) Agonists of gpr131 and uses thereof
TR201109160A2 (tr) Eplerenon içeren yeni farmasötik kompozisyonlar.
GB201116993D0 (en) Pharmaceutical compositions of antihypertensives
PH12017500776A1 (en) Antiperspirant composition